INSMED INC
INSMNASDAQTrading Snapshot
- Day Range
- $114.24 – $117.70
- 52-Week Range
- $90.39 – $212.75
- Volume
- $2.13B
- Avg Volume
- $2.25B
- Shares Outstanding
- 216.8M
- Next Earnings
- Nov 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $606M
- Last Q Revenue
- $425M
- P/E Ratio
- —
- P/S Ratio
- 22.6x
- EPS (TTM)
- $-4.10
- Dividend Yield
- —
- Dilution (1yr)
- +19.3%
Why Investors Own INSM
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INSMED INC
INSM
StockOtter · stockotter.spaceAbout INSMED INC
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the d
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case
Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal competition, and targets $7bn+ peak sales with COPD/asthma comorbidity upsi
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement F
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript